JP2024504372A5 - - Google Patents

Info

Publication number
JP2024504372A5
JP2024504372A5 JP2023544305A JP2023544305A JP2024504372A5 JP 2024504372 A5 JP2024504372 A5 JP 2024504372A5 JP 2023544305 A JP2023544305 A JP 2023544305A JP 2023544305 A JP2023544305 A JP 2023544305A JP 2024504372 A5 JP2024504372 A5 JP 2024504372A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
approximately
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/013417 external-priority patent/WO2022159771A1/en
Publication of JP2024504372A publication Critical patent/JP2024504372A/ja
Publication of JP2024504372A5 publication Critical patent/JP2024504372A5/ja
Pending legal-status Critical Current

Links

JP2023544305A 2021-01-22 2022-01-21 抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質 Pending JP2024504372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163140749P 2021-01-22 2021-01-22
US63/140,749 2021-01-22
PCT/US2022/013417 WO2022159771A1 (en) 2021-01-22 2022-01-21 Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2

Publications (2)

Publication Number Publication Date
JP2024504372A JP2024504372A (ja) 2024-01-31
JP2024504372A5 true JP2024504372A5 (cg-RX-API-DMAC7.html) 2025-01-23

Family

ID=80447580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544305A Pending JP2024504372A (ja) 2021-01-22 2022-01-21 抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質

Country Status (9)

Country Link
US (1) US20250340646A1 (cg-RX-API-DMAC7.html)
EP (1) EP4281186A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024504372A (cg-RX-API-DMAC7.html)
KR (1) KR20230148169A (cg-RX-API-DMAC7.html)
CN (1) CN117083297A (cg-RX-API-DMAC7.html)
AU (1) AU2022211410A1 (cg-RX-API-DMAC7.html)
CA (1) CA3205670A1 (cg-RX-API-DMAC7.html)
IL (1) IL304588A (cg-RX-API-DMAC7.html)
WO (1) WO2022159771A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
AU2022306788A1 (en) * 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
WO2024263698A1 (en) * 2023-06-22 2024-12-26 Memorial Sloan-Kettering Cancer Center Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof
CN120118196A (zh) * 2023-12-08 2025-06-10 百奥泰生物制药股份有限公司 融合蛋白及其应用
WO2025195291A1 (zh) * 2024-03-16 2025-09-25 百奥泰生物制药股份有限公司 治疗肿瘤的方法和用途
WO2026133288A2 (en) * 2024-12-20 2026-06-25 Sanofi IL-2RβΥ BASED LYSOSOMAL DEGRADER AND USES THEREOF

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
ES2774380T3 (es) * 2014-08-29 2020-07-20 Hoffmann La Roche Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA3116188A1 (en) * 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2020081493A1 (en) * 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020165374A1 (en) * 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra

Similar Documents

Publication Publication Date Title
RU2573893C2 (ru) Фармацевтические композиции с устойчивостью к растворимому сеа
JP2022535130A5 (cg-RX-API-DMAC7.html)
JP2022521937A5 (cg-RX-API-DMAC7.html)
JP2022536898A5 (cg-RX-API-DMAC7.html)
CN111527109A (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
JP2021533779A5 (cg-RX-API-DMAC7.html)
HRP20250443T1 (hr) Proteini koji vežu dll3/cd3 za liječenje raka
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
US20240059791A1 (en) Trifunctional fusion protein containing tumor-associated antigen (taa) antibody and application thereof
RU2019129569A (ru) ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
JP2022551081A5 (cg-RX-API-DMAC7.html)
TW201444872A (zh) 抗C-MET串聯Fc雙特異性抗體
JP2022549276A5 (cg-RX-API-DMAC7.html)
JP2023545099A5 (cg-RX-API-DMAC7.html)
WO2022125694A1 (en) Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
JP2023550419A5 (cg-RX-API-DMAC7.html)
JP2023543896A5 (cg-RX-API-DMAC7.html)
JP2023544143A5 (cg-RX-API-DMAC7.html)
CN113490690A (zh) 异源二聚体融合蛋白
JP2024510811A5 (cg-RX-API-DMAC7.html)
Chen et al. Immunoglobulin gamma‐like therapeutic bispecific antibody formats for tumor therapy
JP2024521701A (ja) 抗cd137抗体及びその使用方法
JP2025504795A5 (cg-RX-API-DMAC7.html)
JPWO2022102768A5 (cg-RX-API-DMAC7.html)
CN115746144B (zh) 抗tigit-pd1双特异性抗体及其应用